Anavex Life Sciences Reports Promising Results in Parkinson’s Disease Study
NEW YORK, March 30, 2023 — Anavex has announced encouraging preliminary results from a 48-week Phase 2 extension study on their lead drug candidate, ANAVEX®2-73 […]
NEW YORK, March 30, 2023 — Anavex has announced encouraging preliminary results from a 48-week Phase 2 extension study on their lead drug candidate, ANAVEX®2-73 […]